跳转至内容
Merck
CN

Y0000537

依美斯汀

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C25H34N4O9
化学文摘社编号:
分子量:
534.56
UNSPSC代码:
41116107
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

emedastine

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

N1(CCN(CCC1)c2[n](c3c(n2)cccc3)CCOCC)C.OC(=O)\C=C\C(=O)O.OC(=O)\C=C\C(=O)O

InChI

1S/C17H26N4O.2C4H4O4/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20;2*5-3(6)1-2-4(7)8/h4-5,7-8H,3,6,9-14H2,1-2H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1+

InChI key

FWLKKPKZQYVAFR-LVEZLNDCSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Emedastine difumarate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Peter A D'Arienzo et al.
Clinical therapeutics, 24(3), 409-416 (2002-04-16)
Emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution are 2 topical antiallergic agents available in the United States and other countries. Emedastine is indicated for the temporary relief of the signs and symptoms of allergic conjunctivitis. Ketotifen
C Blondin et al.
Journal francais d'ophtalmologie, 26(4), 328-336 (2003-07-05)
Recent decades have been marked by an increasing number of patients suffering from ocular allergic-like symptoms without being associated with an increase in IgE levels. These symptoms include heaviness of the lid, foreign body sensation, burning, stinging and photophobia. Both
Annemiek Vermeeren et al.
Journal of psychopharmacology (Oxford, England), 16(1), 57-64 (2002-04-13)
Emedastine is registered in its country of origin (Japan) as an antihistamine for the indication of seasonal allergic rhinitis. Further research on the drug's sedating properties was needed to secure its registration elsewhere. The present study was designed to compare
V Orfeo et al.
European journal of ophthalmology, 12(4), 262-266 (2002-09-11)
To assess the efficacy of nedocromil sodium 2% eye drops and emedastine difumarate 0.05% eye drops in controlling the ocular allergic reaction induced by conjunctival allergen challenge (CAC). Thirty subjects with a personal history of allergic conjunctivitis were enrolled (first
Shoichi Harada et al.
Journal of pharmaceutical sciences, 94(1), 17-24 (2005-03-12)
Antihistamine effects of emedastine applied topically with three vehicles varying in their polarities were investigated in rats. The pharmacological effect of emedastine differed greatly depending on its concentration, treatment time, and vehicle. The antihistamine effect reached a plateau after approximately

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持